Fig. 4

SLERCC as a tumor suppressor inhibits the progression of RCC cells in vitro. A Relative expression of SLERCC in different ccRCC cell lines. B Relative expression of SLERCC in 786-O cell lines transfected with PSPM-NPs or Vector. C Relative expression of SLERCC in ACHN cell lines transfected with sh-NC, sh-SLERCC#1, sh-SLERCC#2, or sh-SLERCC#3 constructs. D-E Growth curves of 786-O cells (D) and ACHN cells (E) were measured after transfection with indicated vectors by CCK-8 assays. F, L The migratory capacity of 786-O cells (F) and ACHN cells (L) transfected with indicated vectors assessed by the wound healing assay. G, M Cell migration and invasion of 786-O cells (G) and ACHN cells (M) transfected with indicated vectors assessed by Transwell migration and Matrigel invasion assays. H, K Growth curves of 786-O cells (H) and ACHN cells (K) transfected with indicated vectors assessed by EdU assays. (I, N) The angiogenic capacity of 786-O cells (I) and ACHN cells (N) transfected with indicated vectors assessed by tube formation assay. J, O Stemness of 786-O cells (J) and ACHN cells (O) transfected with indicated vectors assessed by the tumorsphere assay. (*p < 0.05, **p < 0.01, ***p < 0.001)